Scalper1 News
Acquisitions have long been a staple of the drug industry, and a driving force in investment decisions. As the big pharmas’ blockbuster drugs have gone off patent, they’ve filled their pipelines by buying smaller firms with new drugs. For the smaller players, a buyout is usually investors’ chief hope of a healthy return on investment. But while little biotechs are still being bought at a good clip, the buyers are changing. Ernst & Young, in a Scalper1 News
Scalper1 News